Teva : FDA Oks AUSTEDO Tablets For Treatment Of Tardive Dyskinesia In Adults

(RTTNews) - Teva Pharmaceutical Industries Ltd. (TEVA) announced that the U.S. Food and Drug Administration has approved AUSTEDO (deutetrabenazine) tablets for the treatment of tardive dyskinesia in adults.

AUSTEDOwas previously approved for the treatment of chorea associated with Huntington's disease in April 2017.

Tardive dyskinesia is a debilitating and often irreversible movement disorder characterized by repetitive and uncontrollable movements of the tongue, lips, face, trunk and extremities. The condition affects about 500,000 people in the United States and can be caused by certain medications used to treat mental health conditions or gastrointestinal conditions.